Swire Pacific B (00087) spent 1.86 million Hong Kong dollars on repurchasing 187,500 shares on September 20th.
The announcement was made by TAIGU Holdings Company B (00087) on September 20, 2024, stating that the company had invested 186.08...
SWIRE PACIFIC B (00087) announced that the company has repurchased 187,500 shares at a total cost of HK$1.8608 million on September 20, 2024, with a repurchase price ranging from HK$9.76 to HK$9.97 per share.
Related Articles
China Resources Boya Bio-pharmaceutical Group (300294.SZ): Human vasculitis factor for hemophilia approved for clinical trials after process upgrade.
Guangzhou Baiyunshan Pharmaceutical Holdings Branch obtained the Macao Generic Drug Registration Certificate for Cefradine Capsules.
Guosheng: The rebound trend of the pharmaceutical and biotechnology sector has been established. We are optimistic about the innovative drug industry chain and medical technology.
China Resources Boya Bio-pharmaceutical Group (300294.SZ): Human vasculitis factor for hemophilia approved for clinical trials after process upgrade.
Guangzhou Baiyunshan Pharmaceutical Holdings Branch obtained the Macao Generic Drug Registration Certificate for Cefradine Capsules.
Guosheng: The rebound trend of the pharmaceutical and biotechnology sector has been established. We are optimistic about the innovative drug industry chain and medical technology.
RECOMMEND
